Don't Jump to an SGLT2 Inhibitor for Heart Failure

November 2019

You'll hear debate about whether to use an SGLT2 inhibitor (Farxiga, etc) to treat heart failure...in patients withOUT diabetes.

Prior evidence shows that patients WITH diabetes and CV disease or CV risks have fewer heart failure hospitalizations with Farxiga (dapagliflozin), Invokana (canagliflozin), or Jardiance (empagliflozin).

New evidence suggests Farxiga may benefit some heart failure patients...whether or not they have type 2 diabetes.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Safety Put Concerns About Ranitidine and Drug Safety in Perspective
Heart Failure Don't Jump to an SGLT2 Inhibitor for Heart Failure
Medicare Avoid Pitfalls With Medicare Rxs for DME
Diabetes Temper Buzz About the First Oral GLP-1 Agonist, Rybelsus
Diabetes Compare Baqsimi or Gvoke With IM Glucagon for Severe Hypoglycemia
HIV & AIDS Know How Descovy and Truvada Stack Up for HIV Pre-Exposure Prophylaxis (PrEP)
Alcohol Be Ready to Answer the Question, "Is It Okay to Drink Alcohol With This Med?"
Pain Management Consider Acute Pain Management Options for Patients on Buprenorphine/Naloxone
Breast Cancer Weigh Pros and Cons of Meds for Primary Prevention of Breast Cancer
Dermatology Set Realistic Expectations for Patients Asking About Scar Treatments

Don't Jump to an SGLT2 Inhibitor for Heart Failure

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents